Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering.

Receptor change induced by ligand binding is a new issue to face in the field of targeted delivery. Receptor clustering, the main pattern of receptor changes, decreases the affinity between ligand and receptor due to the redistribution of receptor position. In an attempt to respond to such challenge, we designed and constructed three RGD-modified nanocarriers with different ligand intervals: stealth liposomes modified with the monomeric RGD (moRGD-LP), dimeric RGD (diRGD-LP) and a special dimeric RGD with a linker between two cyclic RGD motifs (P-diRGD-LP). The αvβ3-positive and -negative tumor cells (Melanoma B16 and MCF-7) were used as the cell models. As a result, P-diRGD-LP demonstrated strongest interaction with B16 cells in surface plasmon resonance study and highest cellular uptake in B16 cells in real-time confocal analysis. The enhanced endocytosis of P-diRGD-LP was found to be αvβ3-mediated and P-diRGD-LP increased the involvement of the clathrin-dependent pathway. Importantly, P-diRGD-LP demonstrated the best targeting effect in B16-tumor bearing mice in both in vivo and ex vivo near-infrared fluorescent images, about 2.4-fold that of moRGD-LP and 2.8-fold that of diRGD-LP at 3 h. Further, we validated integrin αvβ3 clustering on B16 cells via a single-molecule imaging by a total internal reflection fluorescence microscopy. Finally, the 3D models of αvβ3 clustering suggested a receptor interval within 41.916-65.779 Å, while the molecular computation revealed an RGD ligand interval of 20.944 Å, 42.753 Å and 78.196 Å for diRGD-LP, P-diRGD-LP and moRGD-LP, respectively, confirming the best matching between clustered αvβ3 and P-diRGD-LP. In conclusion, P-diRGD-LP could achieve higher targeting to αvβ3-positive tumor via the enhanced interaction based on the better ligand-receptor compatibility. The design of targeted nanocarriers against receptor clustering might provide new insight into the nanotechnology-based anticancer therapy.

[1]  Xiaoyuan Chen,et al.  Integrin Targeted Delivery of Chemotherapeutics , 2011, Theranostics.

[2]  K. Gottschalk,et al.  A computational model of transmembrane integrin clustering. , 2004, Structure.

[3]  Qiang Zhang,et al.  The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. , 2012, Biomaterials.

[4]  J. Bading,et al.  Integrin αβ3-Targeted Imaging of Lung Cancer , 2005 .

[5]  E. Brǎiloiu,et al.  Crucial Positively Charged Residues for Ligand Activation of the GPR35 Receptor* , 2013, The Journal of Biological Chemistry.

[6]  K. Hunt,et al.  Hurdles and Hopes for Cancer Treatment , 2002, Science.

[7]  M. Hendrix,et al.  Role of the alpha v beta 3 integrin in human melanoma cell invasion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Keishi Suga,et al.  Detection of nanosized ordered domains in DOPC/DPPC and DOPC/Ch binary lipid mixture systems of large unilamellar vesicles using a TEMPO quenching method. , 2013, Langmuir : the ACS journal of surfaces and colloids.

[9]  M. Yeh,et al.  Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells , 2011, International journal of nanomedicine.

[10]  F. Saltel,et al.  The mechanisms and dynamics of αvβ3 integrin clustering in living cells , 2005, The Journal of cell biology.

[11]  Heather Miller,et al.  Ligand mobility regulates B cell receptor clustering and signaling activation. , 2014, Biophysical journal.

[12]  Thilo Stehle,et al.  Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand , 2002, Science.

[13]  G. Kibria,et al.  The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells. , 2013, Biomaterials.

[14]  Yingchun Liu,et al.  Molecular basis for the targeted binding of RGD-containing peptide to integrin αVβ3. , 2014, Biomaterials.

[15]  C. Cremer,et al.  Quantitative analysis of individual hepatocyte growth factor receptor clusters in influenza A virus infected human epithelial cells using localization microscopy. , 2014, Biochimica et biophysica acta.

[16]  P. W. Janes,et al.  Architecture of Eph receptor clusters , 2010, Proceedings of the National Academy of Sciences.

[17]  Erkki Ruoslahti,et al.  Targeting of drugs and nanoparticles to tumors , 2010, The Journal of cell biology.

[18]  Jennifer J Linderman,et al.  Integrin dimerization and ligand organization: key components in integrin clustering for cell adhesion. , 2005, Tissue engineering.

[19]  V. Muzykantov,et al.  Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities , 2012, Science.

[20]  Harvey T. McMahon,et al.  Molecular mechanism and physiological functions of clathrin-mediated endocytosis , 2011, Nature Reviews Molecular Cell Biology.

[21]  A. Beer,et al.  Application of RGD-containing peptides as imaging probes for alphavbeta3 expression. , 2009, Frontiers in bioscience.

[22]  J. Bading,et al.  Integrin alpha v beta 3-targeted imaging of lung cancer. , 2005, Neoplasia.

[23]  Xiaoyuan Chen,et al.  Two ⁹⁰Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy. , 2011, Molecular pharmaceutics.

[24]  E Ruoslahti,et al.  RGD and other recognition sequences for integrins. , 1996, Annual review of cell and developmental biology.

[25]  L. Knight,et al.  Radiopharmaceuticals for targeting the angiogenesis marker αvβ3 , 2003 .

[26]  G. Curley,et al.  A novel approach to determining the affinity of protein-carbohydrate interactions employing adherent cancer cells grown on a biosensor surface. , 2012, Biosensors & bioelectronics.

[27]  Sancey Lucie,et al.  Clustering and Internalization of Integrin αvβ3 With a Tetrameric RGD-synthetic Peptide. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  Qiang Zhang,et al.  Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery. , 2013, Biomaterials.

[29]  S. Gambhir,et al.  microPET Imaging of Glioma Integrin αvβ3 Expression Using 64Cu-Labeled Tetrameric RGD Peptide , 2005 .

[30]  Qiang Zhang,et al.  A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth. , 2013, Biomaterials.

[31]  Shuang Liu.  Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. , 2009, Bioconjugate chemistry.

[32]  Shuang Liu.  Radiolabeled Multimeric Cyclic RGD Peptides as Integrin αvβ3 Targeted Radiotracers for Tumor Imaging , 2006 .

[33]  H. Ghandehari,et al.  HPMA copolymer-cyclic RGD conjugates for tumor targeting. , 2010, Advanced drug delivery reviews.

[34]  C. Souchier,et al.  Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  Shan Wang,et al.  Cholesterol sequestration by nystatin enhances the uptake and activity of endostatin in endothelium via regulating distinct endocytic pathways. , 2011, Blood.

[36]  Markus Schwaiger,et al.  Imaging of integrin αvβ3 expression , 2008, Cancer and Metastasis Reviews.

[37]  Young-Seung Kim,et al.  Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. , 2009, Bioconjugate chemistry.

[38]  H. Harashima,et al.  Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[39]  Erik S. Welf,et al.  A spatial model for integrin clustering as a result of feedback between integrin activation and integrin binding. , 2012, Biophysical journal.

[40]  Bertrand R Caré,et al.  Impact of receptor clustering on ligand binding , 2011, BMC Systems Biology.

[41]  M. Roberge,et al.  Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[42]  L. Knight,et al.  Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3). , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[43]  Shuang Liu.  Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. , 2006, Molecular pharmaceutics.

[44]  Thilo Stehle,et al.  Crystal Structure of the Extracellular Segment of Integrin αVβ3 , 2001, Science.

[45]  D. Diamond,et al.  Development and application of surface plasmon resonance-based biosensors for the detection of cell-ligand interactions. , 2000, Analytical biochemistry.

[46]  Toshio Yanagida,et al.  Single-molecule imaging of EGFR signalling on the surface of living cells , 2000, Nature Cell Biology.

[47]  D. Cheresh,et al.  Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. , 1991, The Journal of clinical investigation.